Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page
- Check2 days agoChange DetectedRevision: v3.4.2 was added and the older funding-status notice (v3.4.1) was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check9 days agoChange DetectedAdded a site-wide notice about funding status and operations and updated the page version from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check16 days agoChange DetectedAdded a 'Show glossary' option and updated footer notes to include 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0', while removing the older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check23 days agoChange DetectedA reference to the 1994 NEJM randomized trial on preoperative chemotherapy plus surgery versus surgery alone in NSCLC was added to the page.SummaryDifference0.1%

- Check30 days agoChange DetectedRevision tag updated to v3.3.4, replacing the previous v3.3.3; this is an internal versioning update with no effect on study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedFooter updated to show Revision: v3.3.3; HHS Vulnerability Disclosure and Revision: v3.3.2 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.